Effect of capsaicin on the climbing ability in drosophila model of Parkinson's disease

American Journal of Drug Discovery and Development

Volumn 2, Issue 1, 2012, Pages 50-54

  Siddique, Y H ^a   Ara, G ^b   Jyoti, S ^a   Afzal, M ^b  

^a Drosophila Transgenic Laboratory   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Capsaicin; Climbing ability; Drosophila; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CAPSAICIN;

AGE; ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; CLIMBING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DROSOPHILA; DRUG EFFECT; DRUG POTENCY; HUMAN; LOCOMOTOR DYSFUNCTION; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE;

EID: 84856822866     PISSN: 2150427X     EISSN: 21504296     Source Type: Journal    
DOI: 10.3923/ajdd.2012.50.54     Document Type: Article

References (25)

1. Amer, D.A., G.B. Irvine and O.M. El-Agnaf, 2006. Inhibitors of α-synuclein oligomerization and toxicity: A future therapeutic strategy for Parkinson's disease and related disorders. Exp. Brain Res., 173: 223-233.
2. Avanesian, A., S. Semmani and M. Jafri, 2009. C. Drosophila melanogast. represent a model system the detection of reproductive adverse drug reactions? Drug Dis. Today, 14: 761-766.
3. Benford, D.J., A.B. Hanley, K. Bottrill, S. Oehlschlager and M. Bal. et al., 2000. Biomarkers as predictive tools in toxicity testing. Alt. Lab Anim., 28: 119-131.
4. Brown, M. and W. Vale, 2011. Effect of neurotensin and substance P on plasma insulin, glucagon and glucose levels. Endrocrinology, 98: 819-822.
5. Caruana, M., T. Hogen, J. Levin, A. Hillmer, A. Giese and N. Vassallo, 2011. Inhibition and disaggregation of alpha Synuclein oligomers by natural polyphenolic compounds. FEBS Lett., 585: 1113-1120.
6. Conway, K.A., J.D. Harper and A.T. Lansbury, 1998. Accelerat. in vit. fibril formation by a mutant alpha synuclein linked to early onset Parkinson disease. Nat. Med., 4: 1318-1320.
7. Dauer, W. and S. Przedborski, 2003. Parkinson's disease: Mechanisms and models. Neuron, 39: 889-909.
8. Fahn, S., 1989. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann. N.Y. Acad. Sci., 570: 186-196.
9. Feany, M.B. and W.W. Bender, 2000. A drosophila model of Parkinson's disease. Nature, 404: 394-398.
10. Festing, M.F.W., V. Baumans, D.R. Combes, M. Halder and F.M. Hendrics. et al., 1998. Reducing the use of laboratory animals in biomedical research: Problems and possible solutions. Alt Lab Anim., 26: 283-301.
11. Fraenkel, L., S.T. Bogardus Jr., J. Concato and D.R. Wittink, 2004. Treatment options in knee Osteoarthritis: The patient's perspective. Arch. Int. Med., 164: 1299-1304.
12. Fujiwake, H., T. Suzuki, S. Oka and K. Iwai, 1980. Enzymatic formation of capsaicinoid from vanillylamine and isotype fatty acids by cell-free extracts. Capsicum annu. var. annum CV. Karayatsubusa. Agric. Biol. Chem., 44: 2907-2912.
13. Giasson, B.I., K. Ury, J.Q. Trojanowski and V.M. Lee, 1999. Mutant and wild type human alpha synuclein assemble into elongated filaments with distinct morphologi. in vitro. J. Biol Chem., 274: 7619-7622.
14. Johnson, W., 2007. Final report on the safety assessment. Capsicum annu. extrac. Capsicum annu. fruit extrac. Capsicum annu. resi. Capsicum annu. fruit powde. Capsicum frutesce. frui. Capsicum frutesce. fruit extrac. Capsicum frutesce. resin and Capsaicin. Int. J. Toxicol., 26: 150-155.
15. Lu, J.M., J. Nurko, S.M. Weakley, J. Jiang and P. Kougl. et al., 2011. Molecular mechanisms and clinical application of nordihydroguaiaretic acid (NDGA) and its derivatives: An update. Med. Sci. Monit., 16: 93-100.
16. Masliah, E., E. Rockenstein, I. Veinbergs, M. Mallory and M. Hashimo. et al., 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implication for neurodegerative disorders. Science, 287: 1265-1269.
17. Mori, A., S. Lehmann, J. O'Kelly, T. Kumagai and J.C. Desmo. et al., 2006. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res., 66: 3222-3229.
18. Naoi, M. and W. Maruyama, 2001. Future of neuroprotection in Parkinson's disease. Parkinson Related Disorder., 8: 139-145.
19. Ono, K. and M. Yamada, 2006. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha synuclein fibri. in vitro. J. Neurochem., 97: 105-115.
20. Pal, R., M. Miranda and M. Narayan, 2011. Nitrosative stress-induced Parkinsonian lewy like aggregates prevented through polyphenolic phytochemical analog intervention. Biochem. Biophys. Res. Commun., 404: 324-329.
21. Pendleton, R.G., F. Parvez, M. Sayed and R. Hillman, 2002. Effects of pharmacological agents upon a transgenic model of Parkinson's disease. Drosophila melanogaster. J. Pharmacol. Exp. Therap., 300: 91-96.
22. Siddique, Y.H., G. Ara, T. Beg, M. Afzal and M. Faisal, 2011. Protective role of Plumbago zeylanica extract against toxic effects of ethinylestradiol in the third instar larvae of transgenic Drosophila melanogaster (hsp70-lacZ)B. and cultured human peripheral blood lymphocytes. Alt. Med. Stud., 7: 26-29.
23. Story, G.M. and C. Orengo, 2007. Feel the burn American. Science, 94: 326-333.
24. Tsui, H., R. Razavi, Y. Chan, J. Yantha and H.M. DoSch, 2007. Sensing autoimmunity in type 1 diabetes. Trend Mol. Med., 130: 405-413.
25. Van der Putten, H., K.H. Wiederhold, A. Probst, S. Barbieri and C. Mis. et al., 2000. Neuropathology in mice expressing human α-synuclein. J. Neurosci., 15: 6021-6029.